Viridian Therapeutics, Inc. VRDN Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s unrealized gains on investments?
- Viridian Therapeutics, Inc. (VRDN) reported unrealized gains on investments of $52K in Q1 2026.
- How has Viridian Therapeutics, Inc.'s unrealized gains on investments changed year-over-year?
- Viridian Therapeutics, Inc.'s unrealized gains on investments decreased by 90.1% year-over-year, from $523K to $52K.
- What is the long-term trend for Viridian Therapeutics, Inc.'s unrealized gains on investments?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s unrealized gains on investments has grown at a 201.4% compound annual growth rate (CAGR), from $6K to $495K.